Combined androgen blockade for advanced prostatic carcinoma

S. Goktas; A. Ziada; E. D. Crawford

doi:10.1038/sj.pcan.4500323

Combined androgen blockade for advanced prostatic carcinoma

S. Goktas, A. Ziada, E. D. Crawford

Department of Urology

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Hormonal therapy has been mainstay of treatment for advanced forms of prostate cancer for over 50 y. The choice of hormonal therapy for carcinoma of the prostate depends not only on the desired progression-free and overall survival but also on the patient's quality of life, treatment costs and treatment toxicities. At the present time, several important questions have been raised over optimal treatment modalities for advanced prostate cancer. The optimal form of this therapy is still an enigma.

Original language	English (US)
Pages (from-to)	172-179
Number of pages	8
Journal	Prostate Cancer and Prostatic Diseases
Volume	2
Issue number	4
DOIs	https://doi.org/10.1038/sj.pcan.4500323
State	Published - Jul 1999

All Science Journal Classification (ASJC) codes

Oncology
Urology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.pcan.4500323

Cite this

@article{4bcf3995a4254122a55e79cdaf0ec10d,

title = "Combined androgen blockade for advanced prostatic carcinoma",

abstract = "Hormonal therapy has been mainstay of treatment for advanced forms of prostate cancer for over 50 y. The choice of hormonal therapy for carcinoma of the prostate depends not only on the desired progression-free and overall survival but also on the patient's quality of life, treatment costs and treatment toxicities. At the present time, several important questions have been raised over optimal treatment modalities for advanced prostate cancer. The optimal form of this therapy is still an enigma.",

author = "S. Goktas and A. Ziada and Crawford, {E. D.}",

year = "1999",

month = jul,

doi = "10.1038/sj.pcan.4500323",

language = "English (US)",

volume = "2",

pages = "172--179",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Combined androgen blockade for advanced prostatic carcinoma

AU - Goktas, S.

AU - Ziada, A.

AU - Crawford, E. D.

PY - 1999/7

Y1 - 1999/7

N2 - Hormonal therapy has been mainstay of treatment for advanced forms of prostate cancer for over 50 y. The choice of hormonal therapy for carcinoma of the prostate depends not only on the desired progression-free and overall survival but also on the patient's quality of life, treatment costs and treatment toxicities. At the present time, several important questions have been raised over optimal treatment modalities for advanced prostate cancer. The optimal form of this therapy is still an enigma.

AB - Hormonal therapy has been mainstay of treatment for advanced forms of prostate cancer for over 50 y. The choice of hormonal therapy for carcinoma of the prostate depends not only on the desired progression-free and overall survival but also on the patient's quality of life, treatment costs and treatment toxicities. At the present time, several important questions have been raised over optimal treatment modalities for advanced prostate cancer. The optimal form of this therapy is still an enigma.

UR - http://www.scopus.com/inward/record.url?scp=0033401227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033401227&partnerID=8YFLogxK

U2 - 10.1038/sj.pcan.4500323

DO - 10.1038/sj.pcan.4500323

M3 - Review article

AN - SCOPUS:0033401227

SN - 1365-7852

VL - 2

SP - 172

EP - 179

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

IS - 4

ER -

Combined androgen blockade for advanced prostatic carcinoma

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this